SG148202A1 - Quinazolinone compounds as anticancer agents - Google Patents

Quinazolinone compounds as anticancer agents

Info

Publication number
SG148202A1
SG148202A1 SG200808730-6A SG2008087306A SG148202A1 SG 148202 A1 SG148202 A1 SG 148202A1 SG 2008087306 A SG2008087306 A SG 2008087306A SG 148202 A1 SG148202 A1 SG 148202A1
Authority
SG
Singapore
Prior art keywords
quinazolinone compounds
anticancer agents
quinazolinone
compounds
alone
Prior art date
Application number
SG200808730-6A
Other languages
English (en)
Inventor
Weibo Wang
Liana M Lagniton
Ryan N Constantine
Manoj C Desai
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Publication of SG148202A1 publication Critical patent/SG148202A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG200808730-6A 2003-11-25 2004-11-24 Quinazolinone compounds as anticancer agents SG148202A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US52505903P 2003-11-25 2003-11-25

Publications (1)

Publication Number Publication Date
SG148202A1 true SG148202A1 (en) 2008-12-31

Family

ID=34632957

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200808730-6A SG148202A1 (en) 2003-11-25 2004-11-24 Quinazolinone compounds as anticancer agents

Country Status (17)

Country Link
US (2) US7939539B2 (https=)
EP (1) EP1689724B1 (https=)
JP (2) JP4778439B2 (https=)
KR (1) KR20060127413A (https=)
CN (1) CN1886384A (https=)
AT (1) ATE538103T1 (https=)
AU (1) AU2004293464A1 (https=)
CA (1) CA2546932A1 (https=)
CY (1) CY1112478T1 (https=)
DK (1) DK1689724T3 (https=)
ES (1) ES2376552T3 (https=)
IL (1) IL175714A0 (https=)
PL (1) PL1689724T3 (https=)
PT (1) PT1689724E (https=)
SG (1) SG148202A1 (https=)
SI (1) SI1689724T1 (https=)
WO (1) WO2005051922A1 (https=)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6545004B1 (en) * 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US7671200B2 (en) * 1999-10-27 2010-03-02 Cytokinetics, Inc. Quinazolinone KSP inhibitors
US7230000B1 (en) * 1999-10-27 2007-06-12 Cytokinetics, Incorporated Methods and compositions utilizing quinazolinones
WO2003070701A2 (en) * 2002-02-15 2003-08-28 Cytokinetics, Inc. Syntheses of quinazolinones
US7214800B2 (en) * 2002-05-09 2007-05-08 Cytokinetics, Inc. Compounds, compositions, and methods
EP1513820A4 (en) 2002-05-23 2006-09-13 Cytokinetics Inc COMPOUNDS, COMPOSITIONS AND METHODS
AU2003256805A1 (en) 2002-07-23 2004-02-09 Cytokinetics, Inc. Compounds compositions and methods
WO2004034972A2 (en) * 2002-09-30 2004-04-29 Cytokinetics, Inc. Compounds, compositions, and methods
NZ551004A (en) 2004-04-02 2010-07-30 Prana Biotechnology Ltd Neurologically-active compounds
CN101027309B (zh) 2004-08-18 2010-10-27 阿斯利康(瑞典)有限公司 所选择的稠合嘧啶酮的对映体和在治疗和预防癌症中的用途
EP1786265A4 (en) * 2004-08-30 2009-08-19 Smithkline Beecham Corp NEW COMPOSITIONS AND PROCESSING METHODS
US20080064680A1 (en) * 2004-09-14 2008-03-13 Bamdad Cynthia C Methods for Diagnosis and Treatment of Cancer
CA2669917A1 (en) 2006-11-17 2008-05-22 Dawn M. George Aminopyrrolidines as chemokine receptor antagonists
KR100916160B1 (ko) * 2007-02-21 2009-09-08 (주)바이오버드 약제학적 항암 조성물
WO2009102537A1 (en) * 2008-02-14 2009-08-20 Merck & Co., Inc. Inhibitors of checkpoint kinases
CN101250189B (zh) * 2008-03-25 2010-06-16 中山大学 双脂肪氨基取代喹唑酮衍生物及其制备方法与作为抗癌药物的应用
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
CN101857595B (zh) * 2010-05-21 2012-11-21 中山大学 一种喹唑酮衍生物及其制备方法和作为抗癌药物的用途
CN101899009B (zh) * 2010-07-30 2012-04-04 江苏昊华精细化工有限公司 医药中间体4(h)喹唑酮的制造方法
CN101967127B (zh) * 2010-09-28 2013-05-29 中山大学 一种喹唑啉衍生物及其制备方法和制备抗癌药物中的应用
DE102012101680A1 (de) * 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Pharmazeutische Zubereitung enthaltend ein antiviral wirksames Dihydrochinazolinderivat
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP2855483B1 (en) 2012-05-24 2017-10-25 Novartis AG Pyrrolopyrrolidinone compounds
CN103012291B (zh) * 2012-12-17 2014-09-03 中山大学 一种2-苯基喹唑啉衍生物及其制备方法与在制备抗癌药物中的应用
NZ708864A (en) 2012-12-21 2016-09-30 Gilead Calistoga Llc Substituted pyrimidine aminoalkyl-quinazolones as phosphatidylinositol 3-kinase inhibitors
JP6207100B2 (ja) 2012-12-21 2017-10-04 ギリアード カリストガ エルエルシー イソキノリノンまたはキナゾリノンホスファチジルイノシトール３−キナーゼ阻害剤
WO2014115080A1 (en) 2013-01-22 2014-07-31 Novartis Ag Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction
US9403827B2 (en) 2013-01-22 2016-08-02 Novartis Ag Substituted purinone compounds
MX2015016344A (es) 2013-05-27 2016-03-01 Novartis Ag Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
CA2912986A1 (en) 2013-05-28 2014-12-04 Novartis Ag Pyrazolo-pyrrolidin-4-one derivatives as bet inhibitors and their use in the treatment of disease
US9714249B2 (en) 2013-05-28 2017-07-25 Novartis Ag Pyrazolo-pyrrolidin-4-one derivatives and their use in the treatment of disease
ES2667173T3 (es) 2013-06-14 2018-05-09 Gilead Calistoga Llc Inhibidores de fosfatidilinositol 3-quinasa
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
MX2021012208A (es) 2013-10-04 2023-01-19 Infinity Pharmaceuticals Inc Compuestos heterocíclicos y usos de los mismos.
US9550796B2 (en) 2013-11-21 2017-01-24 Novartis Ag Pyrrolopyrrolone derivatives and their use as BET inhibitors
PL3086814T3 (pl) 2013-12-23 2020-12-28 Bayer Pharma Aktiengesellschaft Koniugaty środka wiążącego (ADC) z inhibitorami KSP
NZ724368A (en) 2014-03-19 2023-07-28 Infinity Pharmaceuticals Inc Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
US10786578B2 (en) 2014-08-05 2020-09-29 Novartis Ag CKIT antibody drug conjugates
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN107635586B (zh) 2014-12-15 2021-09-24 拜耳医药股份有限公司 Ksp抑制剂与无糖基化抗-tweakr抗体的抗体-药物缀合物(adc)
RU2751512C2 (ru) 2015-06-22 2021-07-14 Байер Фарма Акциенгезельшафт Конъюгаты антитела и лекарственного средства (adc) и конъюгаты антитела и пролекарства (apdc), содержащие ферментативно расщепляемые группы
US11071788B2 (en) 2015-06-23 2021-07-27 Bayer Pharma Aktiengesellschaft Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with antiB7H3-antibodies
WO2016207094A1 (de) 2015-06-23 2016-12-29 Bayer Pharma Aktiengesellschaft Antikörper-wirkstoff-konjugate (adcs) von ksp-inhibitoren mit anti-tweakr-antikörpern
WO2017003723A1 (en) 2015-07-01 2017-01-05 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
EP4585268A3 (en) 2015-09-14 2025-10-15 Twelve Therapeutics, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2017216028A1 (en) 2016-06-15 2017-12-21 Bayer Pharma Aktiengesellschaft Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
JP7066714B2 (ja) 2016-12-21 2022-05-13 バイエル・ファルマ・アクティエンゲゼルシャフト 酵素的に切断可能な基を有する抗体薬物コンジュゲート（ａｄｃ）
JP7030811B2 (ja) 2016-12-21 2022-03-07 バイエル・ファルマ・アクティエンゲゼルシャフト Ｋｓｐ阻害剤を有する特異的抗体－薬物コンジュゲート（ａｄｃ）
US11028068B2 (en) 2017-07-25 2021-06-08 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
JP2021527640A (ja) 2018-06-18 2021-10-14 バイエル アクチェンゲゼルシャフトＢａｙｅｒ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 酵素的に切断可能なリンカーおよび改善された活性プロファイルを有する、ｃｘｃｒ５に対して向けられるバインダー／活性薬剤複合体
CN111499634B (zh) * 2019-01-31 2023-05-12 贝达药业股份有限公司 一种喹唑啉化合物及其在医药上的应用
WO2021086038A1 (ko) 2019-10-31 2021-05-06 홀로스메딕 주식회사 신규한 화합물 및 이를 포함하는 암 예방 또는 치료용 약학 조성물
KR102682775B1 (ko) 2020-06-26 2024-07-08 홀로스메딕 주식회사 신규한 화합물의 제조방법
WO2022231377A1 (ko) 2021-04-29 2022-11-03 홀로스메딕 주식회사 신규한 화합물 및 이를 포함하는 암 예방 또는 치료용 약학 조성물 및 그의 용도
KR102862736B1 (ko) * 2022-12-07 2025-09-22 부산대학교 산학협력단 신규 2-((트랜스-4-(4-아릴옥시)사이클로헥실)아미노)퀴나졸리논 유도체 및 이의 제조방법

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4329418A1 (de) * 1993-09-01 1995-03-02 Agfa Gevaert Ag Gelbkuppler
US6545004B1 (en) * 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
ATE327224T1 (de) * 1999-10-27 2006-06-15 Cytokinetics Inc Chinazolinone benutzende verfahren und zusammenstellungen
JP2002296741A (ja) * 2001-03-30 2002-10-09 Fuji Photo Film Co Ltd 色素形成カプラー、ハロゲン化銀写真感光材料およびアゾメチン色素化合物
US6677110B2 (en) * 2001-03-30 2004-01-13 Fuji Photo Film Co., Ltd. Dye-forming coupler, silver halide photographic light-sensitive material, and azomethine dye compound
JP4267838B2 (ja) * 2001-03-30 2009-05-27 富士フイルム株式会社 色素形成カプラー、ハロゲン化銀写真感光材料およびアゾメチン色素化合物
JP2002318442A (ja) * 2001-04-20 2002-10-31 Fuji Photo Film Co Ltd 色素形成カプラー、ハロゲン化銀写真感光材料およびアゾメチン色素化合物
JP4267840B2 (ja) * 2001-04-20 2009-05-27 富士フイルム株式会社 色素形成カプラー、ハロゲン化銀写真感光材料およびアゾメチン色素化合物
CA2465491A1 (en) 2001-11-07 2003-05-15 Merck & Co., Inc. Mitotic kinesin inhibitors
US7378411B2 (en) * 2001-12-06 2008-05-27 Merck & Co., Inc. Substituted thienopyrimidinones as a mitotic kinesin inhibitor
US7214800B2 (en) 2002-05-09 2007-05-08 Cytokinetics, Inc. Compounds, compositions, and methods
EP1513820A4 (en) 2002-05-23 2006-09-13 Cytokinetics Inc COMPOUNDS, COMPOSITIONS AND METHODS
WO2004039774A2 (en) 2002-05-23 2004-05-13 Merck & Co., Inc. Mitotic kinesin inhibitors
US20040048853A1 (en) 2002-08-21 2004-03-11 Gustave Bergnes Compounds, compositions, and methods
WO2004034972A2 (en) 2002-09-30 2004-04-29 Cytokinetics, Inc. Compounds, compositions, and methods

Also Published As

Publication number Publication date
PT1689724E (pt) 2012-02-06
JP2011084570A (ja) 2011-04-28
EP1689724A1 (en) 2006-08-16
ATE538103T1 (de) 2012-01-15
IL175714A0 (en) 2006-09-05
DK1689724T3 (da) 2012-02-27
WO2005051922A1 (en) 2005-06-09
US20050209254A1 (en) 2005-09-22
CA2546932A1 (en) 2005-06-09
JP4778439B2 (ja) 2011-09-21
CY1112478T1 (el) 2015-12-09
SI1689724T1 (sl) 2012-04-30
KR20060127413A (ko) 2006-12-12
US7939539B2 (en) 2011-05-10
US20110190293A1 (en) 2011-08-04
ES2376552T3 (es) 2012-03-14
AU2004293464A1 (en) 2005-06-09
EP1689724B1 (en) 2011-12-21
JP2007512368A (ja) 2007-05-17
CN1886384A (zh) 2006-12-27
PL1689724T3 (pl) 2012-05-31

Similar Documents

Publication Publication Date Title
SG148202A1 (en) Quinazolinone compounds as anticancer agents
TW200505454A (en) Heteroaryl-fused pyrimidinyl compounds as anticancer agents
WO2005070930A3 (en) Tetrahydrocarboline compounds as anticancer agents
TW200503719A (en) Pyridino [1,2-a] pyrimidin-4-one compounds as anticancer agents
WO2004006859A3 (en) Platinum compound
TW200718689A (en) 2-Amino-quinazolin-5-ones
TNSN08143A1 (en) 2-amino-7,8-dihydro-6h-pyrido[4,3-d]pyrimidin-5-ones
PL377821A1 (pl) 2,4,6-tripodstawione pirymidyny jako inhibitory kinazy fosfatydyloinozytolu (PI) 3 i ich zastosowanie w leczeniu nowotworu
BG108269A (en) Pyrazolopyrimidines as therapeutic agents
WO2004030627A3 (en) Synergistic methods and compositions for treating cancer
TW200631578A (en) Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury
AP1913A (en) Substituted benzazoles and use thereof as raf kinase inhibitors
BG108268A (en) Pyrazolopyrimidines as therapeutic agents
CR8181A (es) Uso de una combinacion de un inhibidor de la cinasa del receptor del factor de crecimiento epidermico y agentes citotoxicos para el tratamiento e inhibicion del cancer
IL176110A0 (en) Azabicyclic heterocycles as cannabinoid receptor modulators
WO2005004808A3 (en) TETRACYCLIC COMPOUNDS AS c-MET INHIBITORS
MX2007006066A (es) Inhibidores de jnk para el tratamiento de lesiones del snc.
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
TW200505443A (en) Combination of SCR kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases
ZA202210640B (en) Deuterated oxophenylarsine compound and use thereof
TWI340639B (en) Pharmaceutical composition for treating luts, other than urinary incontinence, associated with oab and/or bph
TW200420290A (en) Methods for the treatment, prevention and management of macular degeneration
MX2021011289A (es) Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas.
MX2010004314A (es) Compuestos para inhibir la actividad de quinesina de la proteina quinesina del huso.
MX2010005009A (es) Uso de compuestos inmunomoduladores para el tratamiento de trastornos asociados con disfunciones endoteliales.